肺炎克雷伯菌肝脓肿患者临床特征分析*

doi:10.3969/j.issn.1672-5069.2024.01.031

摘要/Abstract

摘要： 目的回顾分析总结细菌性肝脓肿(PLA),特别是肺炎克雷伯菌(KP)肝脓肿患者病原学、影像学表现和治疗效果,以提高对该病的诊治水平。方法 2017年1月～2022年5月我院收治的PLA患者110例,给予抗感染和超声引导下穿刺抽脓治疗,行血或/和脓液培养。采用化学发光法检测血清高敏C反应蛋白(hs-CRP),采用双抗体夹心免疫发光法检测血清降钙素原(PCT);采用Clauss法检测血清纤维蛋白原。结果在本组110例PLC患者中,血培养或脓液培养阳性70例(63.6%),其中KP 48例(68.6%),大肠杆菌7例(10.0%),链球菌4例(5.7%),葡萄球菌3例(4.3%),粪肠球菌3例(4.3%),屎肠球菌2例(2.8%),解鸟氨酸拉乌尔菌、肠炎沙门氏菌和奇异变形杆菌各1例(4.3%);在70例细菌培养阳性的PLA患者中,肺炎克雷伯菌肝脓肿(KPLA)48例,非肺炎克雷伯菌肝脓肿(N-KPLA)22例;KPLA组年龄为58(49,66)岁,显著年轻于N-KPLA组【65(61,74)岁,P<0.05】;KPLA组合并糖尿病、胆系手术史和胆系感染发生率分别为56.2%、8.3%和14.6%,与N-KPLA组的22.7%、27.3%和45.4%比,差异显著(P<0.05);KPLA组血肌酐(sCr)、高敏C反应蛋白(hs-CRP)、降钙素原(PCT)和纤维蛋白原分别为88.7(60.8,115.4)μmol/L、170.5(86.3,240.5)mg/L、20.2(9.8,31.5)ng/L和6.4(5.0,7.8)g/L,与N-KPLA组【分别为100.3(62.3,145.0)μmol/L、132.6(60.6,181.2)mg/L、26.8(13.4,40.6)ng/L和5.3(4.3,7.1)g/L】比,差异具有统计学意义(P<0.05);影像学检查发现,KPLA组薄壁脓腔、脓腔分隔、脓液液化发生率分别为83.3%、62.5%和97.9%,均显著高于N-KPLA组的54.5%、31.8%和72.7%(P<0.05);在48例KPLA患者中,短期治愈率为70.8%,在N-KPLA患者为59.1%,两组住院时间分别为20(15,28)d和22(16,28)d(P>0.05)。结论在PLA患者中,常见的病原体为KP,了解其发病和脓腔特征,给予抗感染和穿刺抽脓治疗,大多预后良好。

关键词: 细菌性肝脓肿, 肺炎克雷伯菌, 穿刺引流, 治疗

Abstract: Objective The purpose of this study was to summarize the clinical features of Klebsiella Pneumonia (KP)-induced bacterial liver abscess (PLA). Methods 110 patients with PLA were encountered in our hospital between January 2017 and May 2022, and all patients were treated by needle puncture and drainage under US guidance at base of intravenous administration of antibiotics. Serum high sensitivity C-reactive protein (hs-CRP), procalcitonin (PCT) and fibrinogen (Fib) levels were detected. Results Out of the 110 patients with PLA, the bacteria culture found positive in 70 (63.6%) patients, including KP in 48 cases (68.6%), Escherichia Coli in 7 cases (10.0%), Streptococcus in 4 cases (5.7%), Staphylococcus in 3 cases (4.3%), Enterococcus Faecalis in 3 cases (4.3%), Enterococcus Faecalis in 2 cases (2.8%) and others in 3 cases (4.3%); the KP-induced PLA (KPLA) accounted for 68.6% (48/70), and non-KP-induced PLA (N-KPLA) for 31.4% (22/70); the age of patients with KPLA was 58(49,66)yr, much younger than [65(61, 74)yr, P<0.05] in patients with N-KPLA; there were significant differences as respect to the incidences of concomitant diabetes, biliary operation histories and biliary infections between the two groups (56.2%, 8.3% and 14.6% vs. 22.7%, 27.3% and 45.4%, P<0.05); the sCr, serum hs-CRP, PCT and Fib levels in patients with KPLA were 88.7(60.8, 115.4)μmol/L, 170.5(86.3, 240.5)mg/L, 20.2(9.8, 31.5)ng/L and 6.4(5.0, 7.8)g/L, all significant different compared to [100.3(62.3, 145.0)μmol/L, 132.6(60.6, 181.2)mg/L, 26.8(13.4, 40.6)ng/L and 5.3(4.3, 7.1)g/L] in patients with N-KPLA(P<0.05); the imaging scan found that the incidences of thin wall of intrahepatic abscess, separated abscess and liquidation of abscess in patients with KPLA were 83.3%, 62.5% and 97.9%, all much higher than 54.5%, 31.8% and 72.7%(P<0.05) in patients with N-KPLA; the short-term recovery rate in the 48 patients with KPLA was 70.8%, a little bit higher than 59.1% in patients with N-KPLA, and the hospital stay were 20(15, 28)d and 22(16, 28)d(P>0.05) between the two groups. Conclusion The common pathogen of PLA is KP, followed by Escherichia Coli. The clinicians should take the clinical features of PLA, especially those with KP infections, might help making an appropriate measures to deal with it.

Key words: Bacterial liver abscess, Klebsiella Pneumoniae, Puncture drainage, Therapy

郑浩, 王洪剑, 刘晶晶. 肺炎克雷伯菌肝脓肿患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 121-124.

Zheng Hao, Wang Hongjian, Liu Jingjing. Clinical features of Klebsiella Pneumonia-induced bacterial liver abscess[J]. Journal of Practical Hepatology, 2024, 27(1): 121-124.

参考文献

[1] Serraino C, Elia C, Bracco C, et al. Characteristics and management of pyogenic liver abscess: A European experience. Medicine (Baltimore), 2018, 97(19):e0628.
[2] Zhang S, Zhang X, Wu Q, et al. Clinical, microbiological, and molecular epidemiological characteristics ofKlebsiella pneumoniae-induced pyogenic liver abscess in southeastern China. Antimicrob Resist Infect Control, 2019, 8:166.
[3] Kim E, Park DH, Kim KJ, et al. Current status of amebic liver abscess in Korea comparing with pyogenic liver abscess. Korean J Gastroenterol, 2020, 76(1):28-36.
[4] Hsu YL, Lin HC, Yen TY, et al. Pyogenic liver abscess among children in a medical center in Central Taiwan. J Microbiol Immunol Infect, 2015, 48(3):302-305.
[5] Sun R, Zhang H, Xu Y, et al.Klebsiella pneumoniae-related invasive liver abscess syndrome complicated by purulent meningitis: a review of the literature and description of three cases. BMC Infect Dis, 2021, 21(1):15.
[6] Wang G, Zhao G, Chao X, et al. The characteristic of virulence, biofilm and antibiotic resistance ofKlebsiella pneumoniae. Int J Environ Res Public Health, 2020, 17(17):6278.
[7] Liang X, Chen P, Deng B, et al. Outcomes and risk factors of bloodstream infections caused by carbapenem-resistant and non-carbapenem-resistant Klebsiella pneumoniae in China. Infect Drug Resist, 2022, 15:3161-3171.
[8] Paczosa MK, Mecsas J.Klebsiella pneumoniae: Going on the offense with a strong defense. Microbiol Mol Biol Rev, 2016, 80(3):629-661.
[9] Struve C, Roe CC, Stegger M, et al. Mapping the evolution of hypervirulentKlebsiella pneumoniae. mBio, 2015, 6(4):e00630.
[10] 李彤寰. 糖尿病合并肺炎克雷伯杆菌性肝脓肿的临床特点及误诊分析. 临床肝胆病杂志, 2009, 25(4):266-268.
[11] 何蕾, 阴晴, 吴亮, 等. 肺炎克雷伯菌所致肝脓肿患者的临床特征及毒力基因检测. 中国感染控制杂志, 2021, 20(7):619-625.
[12] 吴华, 李东冬, 王京, 等. 肺炎克雷伯菌肝脓肿的临床及微生物特征分析. 中华医学杂志, 2015, 95(40):3259-3263.
[13] 王军大, 杨华, 赵建宁, 等. 糖尿病患者肺炎克雷伯杆菌肝脓肿并发血源性肺部感染CT征象回归分析. 中国CT和MRI杂志, 2020, 18(9):69-72.
[14] Du ZQ, Zhang LN, Lu Q, et al. Clinical charateristics and outcome of pyogenic liver abscess with different size: 15-year experience from a single center. Sci Rep, 2016, 6:35890.
[15] Kong H, Yu F, Zhang W, et al. Clinical and microbiological characteristics of pyogenic liver abscess in a tertiary hospital in East China. Medicine (Baltimore), 2017, 96(37):e8050.
[16] 黄洋, 张伟辉. 细菌性肝脓肿的诊治进展. 临床肝胆病杂志, 2018, 34(3):641-644.
[17] Tian LT, Yao K, Zhang XY, et al. Liver abscesses in adult patients with and without diabetes mellitus: an analysis of the clinical characteristics, features of the causativepathogens, outcomes and predictors of fatality: a report based on a large population, retrospective study in China. Clin Microbiol Infect, 2012, 18(9):E314-E330.
[18] 徐圣, 石宝琪, 朝鲁孟, 等. 经皮穿刺置管引流术治疗不同糖化血红蛋白水平糖尿病肝脓肿患者的预后分析. 中国介入影像与治疗学, 2019, 16(9):550-554.
[19] Wang F,Yu J, Chen W, et al. Clinical characteristics of diabetes complicated by bacterial liver abscess and nondiabetes-associated liver abscess. Dis Markers, 2022, 2022:7512736.
[20] Ejikeme C, Nwachukwu O, Ayad S, et al. Hepatosplenic abscess fromKlebsiella pneumoniae in poorly controlled diabetic. J Investig Med High Impact Case Rep, 2021, 9:23247096211033046.

肺炎克雷伯菌肝脓肿患者临床特征分析^*

Clinical features of Klebsiella Pneumonia-induced bacterial liver abscess

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈从新, 陈曦, 王莉苹, 赵秋香, 刘颖, 周海洋. 糖皮质激素在肝病治疗中的应用[J]. 实用肝脏病杂志, 2024, 27(3): 321-323.
[2]	赵玉雯, 朱传龙. 肝硬化营养不良及肌少症治疗研究进展[J]. 实用肝脏病杂志, 2024, 27(3): 324-328.
[3]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[4]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[5]	程艳洁, 王鹏飞, 李峻. 水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 349-352.
[6]	徐秋萍, 黄彬, 陈敏, 余静. 泼尼松与泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者外周血MDSCs百分比、肝组织白细胞介素-35和血清CD38水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 374-377.
[7]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[8]	李菊兰, 张华堂, 郑怡娟, 余雪平, 邓勇, 苏智军. 恩替卡韦联合扶正化瘀片治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 402-405.
[9]	蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东. 基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(3): 406-409.
[10]	闫振, 赵博文, 林国英, 殷和良. 影像学三维可视化技术指导肝切除术治疗肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 438-441.
[11]	李玮健, 刘昕, 舒红艳. 超声引导下聚桂醇与无水乙醇注射硬化治疗肝囊肿患者疗效比较研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 450-453.
[12]	王苓入, 苏虹, 郝晓炜, 李娜. 超声引导下PTGD联合聚桂醇硬化治疗单纯性肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 454-457.
[13]	徐旭, 施漪雯, 范建高. 肝豆状核变性治疗现状与展望^*[J]. 实用肝脏病杂志, 2024, 27(3): 477-480.
[14]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[15]	李兴泉, 杨春, 李诗源, 翁凯, 彭麟. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 177-180.